- Home
- AGEN vs CVKD Comparison
AGEN vs CVKD Comparison
Compare AGEN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- CVKD
- Stock Information
- Founded
- AGEN 1994
- CVKD 2022
- Country
- AGEN United States
- CVKD United States
- Employees
- AGEN N/A
- CVKD N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- AGEN Health Care
- CVKD Health Care
- Exchange
- AGEN Nasdaq
- CVKD Nasdaq
- Market Cap
- AGEN 38.1M
- CVKD 31.5M
- IPO Year
- AGEN 2000
- CVKD 2023
- Fundamental
- Price
- AGEN $3.16
- CVKD $16.66
- Analyst Decision
- AGEN Buy
- CVKD Strong Buy
- Analyst Count
- AGEN 4
- CVKD 1
- Target Price
- AGEN $8.00
- CVKD $32.00
- AVG Volume (30 Days)
- AGEN 655.0K
- CVKD 20.7K
- Earning Date
- AGEN 05-06-2025
- CVKD 05-08-2025
- Dividend Yield
- AGEN N/A
- CVKD N/A
- EPS Growth
- AGEN N/A
- CVKD N/A
- EPS
- AGEN N/A
- CVKD N/A
- Revenue
- AGEN $103,463,000.00
- CVKD N/A
- Revenue This Year
- AGEN $4.03
- CVKD N/A
- Revenue Next Year
- AGEN $5.57
- CVKD N/A
- P/E Ratio
- AGEN N/A
- CVKD N/A
- Revenue Growth
- AGEN N/A
- CVKD N/A
- 52 Week Low
- AGEN $1.38
- CVKD $5.70
- 52 Week High
- AGEN $19.69
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- AGEN 78.44
- CVKD 48.07
- Support Level
- AGEN $1.60
- CVKD $15.85
- Resistance Level
- AGEN $1.83
- CVKD $17.33
- Average True Range (ATR)
- AGEN 0.31
- CVKD 1.41
- MACD
- AGEN 0.21
- CVKD 0.16
- Stochastic Oscillator
- AGEN 97.52
- CVKD 63.03
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.